JP2023549522A - がん予防における短鎖脂肪酸の使用 - Google Patents

がん予防における短鎖脂肪酸の使用 Download PDF

Info

Publication number
JP2023549522A
JP2023549522A JP2023528582A JP2023528582A JP2023549522A JP 2023549522 A JP2023549522 A JP 2023549522A JP 2023528582 A JP2023528582 A JP 2023528582A JP 2023528582 A JP2023528582 A JP 2023528582A JP 2023549522 A JP2023549522 A JP 2023549522A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
administered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549522A5 (enExample
Inventor
エー．フェイテルソン マーク
アルズマンヤン アラ
シー．スペクター イラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Publication of JP2023549522A publication Critical patent/JP2023549522A/ja
Publication of JP2023549522A5 publication Critical patent/JP2023549522A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023528582A 2020-11-12 2021-11-12 がん予防における短鎖脂肪酸の使用 Pending JP2023549522A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112783P 2020-11-12 2020-11-12
US63/112,783 2020-11-12
PCT/US2021/059211 WO2022104116A1 (en) 2020-11-12 2021-11-12 Use of short chain fatty acids in cancer prevention

Publications (2)

Publication Number Publication Date
JP2023549522A true JP2023549522A (ja) 2023-11-27
JP2023549522A5 JP2023549522A5 (enExample) 2024-12-06

Family

ID=81601740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528582A Pending JP2023549522A (ja) 2020-11-12 2021-11-12 がん予防における短鎖脂肪酸の使用

Country Status (8)

Country Link
US (1) US20240009155A1 (enExample)
EP (1) EP4243803A4 (enExample)
JP (1) JP2023549522A (enExample)
KR (1) KR20230127990A (enExample)
CN (1) CN116782949A (enExample)
AU (1) AU2021380836A1 (enExample)
CA (1) CA3198162A1 (enExample)
WO (1) WO2022104116A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137671A1 (en) 2023-12-22 2025-06-26 Temple University-Of The Commonwealth System Of Higher Education Short chain fatty acid compounds and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018504457A (ja) * 2015-01-23 2018-02-15 テンプル ユニヴァーシティ − オブ ザ コモンウェルス システム オブ ハイアー エデュケーション ガン予防における短鎖脂肪酸の使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030020482A (ko) * 2001-08-29 2003-03-10 대한민국(서울대학교) 소디움부티레이트를 유효성분으로 하는 항암제
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
WO2018089861A1 (en) * 2016-11-11 2018-05-17 The Regents Of The University Of California Methods and compositions for the treatment of cancer and metabolic diseases
WO2018140687A1 (en) * 2017-01-27 2018-08-02 Temple University-Of The Commonwealth System Of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
AU2019358875B2 (en) * 2018-10-09 2025-08-21 Monash University Combination therapy for treatment and prevention of autoimmune and inflammatory diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018504457A (ja) * 2015-01-23 2018-02-15 テンプル ユニヴァーシティ − オブ ザ コモンウェルス システム オブ ハイアー エデュケーション ガン予防における短鎖脂肪酸の使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JI-WON JUNG ET AL., CANCER LETTERS, vol. 225, JPN6025040371, 2005, pages 199 - 206, ISSN: 0005849491 *
NOREEN MCBREARTY: "Short Chain Fatty Acids(SCFAS) Delay the Pathogenesis of Hepatitis B virus(HBV)-associated Hepatocel", PHD THESIS, THE TEMPLE UNIVERSITY, JPN6025040372, 2019, ISSN: 0005849490 *

Also Published As

Publication number Publication date
WO2022104116A1 (en) 2022-05-19
EP4243803A1 (en) 2023-09-20
AU2021380836A1 (en) 2023-06-22
EP4243803A4 (en) 2024-10-23
KR20230127990A (ko) 2023-09-01
US20240009155A1 (en) 2024-01-11
CA3198162A1 (en) 2022-05-19
CN116782949A (zh) 2023-09-19

Similar Documents

Publication Publication Date Title
Flaig et al. A study of high‐dose oral silybin‐phytosome followed by prostatectomy in patients with localized prostate cancer
Tozaki et al. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
WO2005082349A1 (en) Composition for the treatment of obesity comprising fumagillol derivative
Sharman et al. Cyclic-GMP–Elevating agents suppress polyposis in Apc min mice by targeting the preneoplastic epithelium
EP4406538A1 (en) Treatment of cancer patients having kras mutations
US20240398789A1 (en) Pharmaceutical composition for enhancing anti-tumor effect of ezh2 inhibitor and use thereof
JP7120691B2 (ja) 非アルコール性脂肪肝炎の予防または治療用の薬学組成物
Zhou et al. NF‐κB Inhibitor Myrislignan Induces Ferroptosis of Glioblastoma Cells via Regulating Epithelial‐Mesenchymal Transformation in a Slug‐Dependent Manner
Sun et al. Dehydrocostus lactone alleviates irinotecan-induced intestinal mucositis by blocking TLR4/MD2 complex formation
WO2025113500A1 (zh) 吲哚丙酸在治疗自身免疫性肝损伤和肝硬化中的应用
JP5930204B2 (ja) 癌細胞アポトーシス
KR20230127990A (ko) 암 예방에서 단쇄 지방산의 용도
KR102684334B1 (ko) 지방간염, 지방증 또는 섬유증의 예방 또는 치료용 복합 제제
CN116850289A (zh) Plk4靶向药物在治疗对铂类药物耐药型肿瘤中的应用
EP4104823A1 (en) Inhibitor of aspartic acid synthesis in tumor cells, inhibitor of spheroid formation of tumor cells, inhibitor of tumor cell metastasis, activity enhancer of glycolytic inhibitor, and pharmaceutical composition for suppressing and/or preventing tumor metastasis
WO2021036537A1 (zh) 钩吻素子在制备用于治疗炎症性肠病的药物中的用途
US20240122956A1 (en) Application of Naringin Combined with Rapamycin in Preparation of Medications for Treating Hyperlipidemia
Choy et al. Clinical study SARC018_SPORE02: phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
JP2026500734A (ja) 医薬組み合わせ、及びその使用
WO2025056055A1 (zh) 新一代egfr抑制剂单药或联合使用在制备肿瘤疾病的药物中的应用
EA053053B1 (ru) Способы терапии посредством подавления ezh2 для лечения видов рака, связанного с мутантным белком 1а, содержащим ат-богатый интерактивный домен (arid1a)
Yura et al. Hexamethylene bisacetamide as a chemopreventive agent in hamster cheek pouch tumorigenesis
Sorbera RDP-58

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260428